Shionogi’s first investment under its Corporate Venture Capital (CVC) activities

盐野义制药在其企业风险投资（CVC）活动中的首次投资

Shionogi & Co. has made an equity investment in Restore Vision Inc, a Tokyo-based startup company developing innovative technologies in the field of ophthalmology. This investment represents Shionogi’s first investment under its Corporate Venture Capital (CVC) activities.

盐野义制药公司对东京初创公司Restore Vision Inc.进行了股权投资，该公司致力于开发眼科领域的创新技术。这项投资标志着盐野义制药在其企业风险投资（CVC）活动中的首次投资。

In April 2025, Shionogi established its Corporate Venture Capital (CVC) to explore next-generation growth opportunities in new markets and technology areas. The CVC targets a broad range of investment areas beyond pharmaceuticals, including technology, infrastructure, and resources. Through these activities, Shionogi seeks to create new value that contributes to addressing social challenges and advancing healthcare..

2025年4月，盐野义制药设立了企业风险投资（CVC），以探索新市场和技术领域中的下一代增长机会。该CVC的目标投资领域广泛，不仅限于制药，还包括技术、基础设施和资源等领域。通过这些活动，盐野义旨在创造有助于应对社会挑战和推动医疗健康发展的新价值。

Through its CVC activities, Shionogi aims to build early-stage partnerships with startup companies that possess innovative technologies and business ideas, supporting them by leveraging Shionogi’s research and development capabilities, business experience, and network—thereby fostering relationships that contribute to mutual growth..

通过其企业风险投资活动，盐野义制药旨在与拥有创新技术和商业理念的初创公司建立早期合作关系，利用盐野义的研发能力、业务经验及网络支持这些公司，从而促进双方共同成长的关系。

Restore Vision Inc. is a startup aiming to realise a visual restoration gene therapy using its unique functional gene coding “Chimeric Rhodopsin,” which is a protein-based optical sensor. The company’s technology is expected to contribute to addressing social challenges associated with blindness caused by retinal disorders, for which effective preventive or curative treatments have not yet been established, including the hardships experienced by patients and the burden on those around them..

恢复视力公司是一家初创企业，致力于利用其独特的功能基因编码“嵌合视紫红质”来实现视觉恢复的基因疗法，这是一种基于蛋白质的光学传感器。该公司技术有望为解决由视网膜疾病导致的失明相关的社会挑战做出贡献，目前对于这些疾病尚无有效的预防或治疗方法，患者及其周围人所承受的痛苦和负担也有待减轻。